Loading...
Sign in to edit your profile (add interests, mentoring, photo, etc.)

    Isabelle Tancioni

    TitleAssistant Project Scientist
    SchoolUniversity of California, San Diego
    DepartmentReproductive Medicine
    Address9500 Gilman Drive #0803
    CA La Jolla 92093
    Phone858-822-0597
    vCardDownload vCard

      Collapse Bibliographic 
      Collapse Publications
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
      List All   |   Timeline
      1. Delaney JR, Patel CB, Willis KM, Haghighiabyaneh M, Axelrod J, Tancioni I, Lu D, Bapat J, Young S, Cadassou O, Bartakova A, Sheth P, Haft C, Hui S, Saenz C, Schlaepfer DD, Harismendy O, Stupack DG. Haploinsufficiency networks identify targetable patterns of allelic deficiency in low mutation ovarian cancer. Nat Commun. 2017 Feb 15; 8:14423. PMID: 28198375.
        View in: PubMed
      2. Delaney JR, Patel C, McCabe KE, Lu D, Davis MA, Tancioni I, von Schalscha T, Bartakova A, Haft C, Schlaepfer DD, Stupack DG. A strategy to combine pathway-targeted low toxicity drugs in ovarian cancer. Oncotarget. 2015 Oct 13; 6(31):31104-18. PMID: 26418751.
        View in: PubMed
      3. Tancioni I, Miller NL, Uryu S, Lawson C, Jean C, Chen XL, Kleinschmidt EG, Schlaepfer DD. FAK activity protects nucleostemin in facilitating breast cancer spheroid and tumor growth. Breast Cancer Res. 2015; 17(1):47. PMID: 25880415.
        View in: PubMed
      4. Tancioni I, Uryu S, Sulzmaier FJ, Shah NR, Lawson C, Miller NL, Jean C, Chen XL, Ward KK, Schlaepfer DD. FAK Inhibition Disrupts a ß5 Integrin Signaling Axis Controlling Anchorage-Independent Ovarian Carcinoma Growth. Mol Cancer Ther. 2014 Aug; 13(8):2050-61. PMID: 24899686.
        View in: PubMed
      5. Shah NR, Tancioni I, Ward KK, Lawson C, Chen XL, Jean C, Sulzmaier FJ, Uryu S, Miller NL, Connolly DC, Schlaepfer DD. Analyses of merlin/NF2 connection to FAK inhibitor responsiveness in serous ovarian cancer. Gynecol Oncol. 2014 Jul; 134(1):104-11. PMID: 24786638.
        View in: PubMed
      6. Jean C, Chen XL, Nam JO, Tancioni I, Uryu S, Lawson C, Ward KK, Walsh CT, Miller NL, Ghassemian M, Turowski P, Dejana E, Weis S, Cheresh DA, Schlaepfer DD. Inhibition of endothelial FAK activity prevents tumor metastasis by enhancing barrier function. J Cell Biol. 2014 Jan 20; 204(2):247-63. PMID: 24446483.
        View in: PubMed
      7. Miller NL, Lawson C, Kleinschmidt EG, Tancioni I, Uryu S, Schlaepfer DD. A non-canonical role for Rgnef in promoting integrin-stimulated focal adhesion kinase activation. J Cell Sci. 2013 Nov 1; 126(Pt 21):5074-85. PMID: 24006257.
        View in: PubMed
      8. Ward KK, Tancioni I, Lawson C, Miller NL, Jean C, Chen XL, Uryu S, Kim J, Tarin D, Stupack DG, Plaxe SC, Schlaepfer DD. Inhibition of focal adhesion kinase (FAK) activity prevents anchorage-independent ovarian carcinoma cell growth and tumor progression. Clin Exp Metastasis. 2013 Jun; 30(5):579-94. PMID: 23275034.
        View in: PubMed
      9. Lim ST, Miller NL, Chen XL, Tancioni I, Walsh CT, Lawson C, Uryu S, Weis SM, Cheresh DA, Schlaepfer DD. Nuclear-localized focal adhesion kinase regulates inflammatory VCAM-1 expression. J Cell Biol. 2012 Jun 25; 197(7):907-19. PMID: 22734001.
        View in: PubMed
      10. Chen XL, Nam JO, Jean C, Lawson C, Walsh CT, Goka E, Lim ST, Tomar A, Tancioni I, Uryu S, Guan JL, Acevedo LM, Weis SM, Cheresh DA, Schlaepfer DD. VEGF-induced vascular permeability is mediated by FAK. Dev Cell. 2012 Jan 17; 22(1):146-57. PMID: 22264731.
        View in: PubMed